Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01049854 · ClinicalTrials.gov registry record · Phase 2

CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

A Phase 2 study of Lymphoma and Leukemia, sponsored by New York Medical College.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT01049854: Completed Phase 2 study of Lymphoma and Leukemia, sponsored by New York Medical College.

NCT01049854 is a Phase 2 study of Lymphoma and Leukemia that has completed, run by New York Medical College. The registered enrollment target is 20 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01049854, a Phase 2 study of Lymphoma and Leukemia, has completed, sponsored by New York Medical College.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

CD34+ stem cell selection in children, adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious (Grade III/IV) acute and chronic graft versus host disease (GVHD).

Primary Outcome

serious adverse events will be monitored post transplant to determine if there is an increase vs. historical data related to the CD34+ selection

Interventions

  • DRUG Full Intensity with TBI
  • DRUG Full Intensity
  • DRUG Reduced Intensity
  • DRUG Reduced Intensity (Fanconi)

Study Locations (1)

New York

  • New York Medical College - Valhalla

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-09
Est. Completion 2018-08
Phase Phase 2
New York Medical College

47 total trials

What the finished NCT01049854 record still lists

NCT01049854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (96% lower).

The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Full Intensity with TBI is the first listed.

NCT01049854 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01049854 about?

NCT01049854 is a clinical study titled "CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant". CD34+ stem cell selection in children, adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious (Grade III/I...

What is the current status of trial NCT01049854?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-09. Estimated completion is 2018-08.

What conditions does trial NCT01049854 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia, Sickle Cell Disease, Beta-Thalassemia, Immunodeficiencies.

What interventions are being tested in trial NCT01049854?

The interventions under investigation include: Full Intensity with TBI (DRUG), Full Intensity (DRUG), Reduced Intensity (DRUG), Reduced Intensity (Fanconi) (DRUG).

Who is sponsoring clinical trial NCT01049854?

This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01049854 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01049854's enrollment target sits among peer trials

20 246th of 299 higher than 49 of 299 other Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01049854, the US trial registry maintained by the National Library of Medicine. NCT01049854 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.